TerminatedPhase 2NCT03791060
Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
Studying Necrobiosis lipoidica
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beth Israel Deaconess Medical Center
- Principal Investigator
- Alexa Kimball, MD MPHBeth Israel Deaconess Medical Center
- Intervention
- Secukinumab(drug)
- Enrollment
- 4 target
- Eligibility
- 18-110 years · All sexes
- Timeline
- 2019 – 2021
Study locations (1)
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Collaborators
Novartis Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03791060 on ClinicalTrials.gov